Harmony Biosciences Holdings, Inc. (HRMY) Form 10-Q — Nov 4, 2026
Harmony Biosciences reported Q3 2026 net product revenue of $268.9 million, up 12.3% year-over-year, driven by 7.5% unit growth and a 7% price increase. However, quarterly net income slipped to $48.2 million from $50.9 million a year ago as cost of product sold jumped 35.3% on new Novitium royalties and R&D expense rose 30.4% including a $25 million MSN milestone IPR&D charge. For the nine months, revenue grew 19.4% to $745.6 million with net income of $156.1 million and $196.9 million in operating cash flow. The company holds $1,052.0 million in cash and investments against $150.0 million of debt and used no shares under its $150 million remaining buyback authorization in 2026.
Key figures
- Eps
- 0.81
- Revenue
- 745584000
- Net Income
- 156115000
- Total Debt
- 150000000
- Revenue Yoy
- 19.4% (nine months)
- Cash Position
- $1,052.0 million (cash, equivalents and investments)
- Shares Outstanding
- 58723199
- Q3 revenue
- $268.9 million (+12.3% YoY)
- Q3 basic eps
- $0.83
- Q3 net income
- $48.2 million (vs $50.9 million prior year)
- Q3 diluted eps
- $0.81
- Wakix avg patients q3
- approximately 9,350
- Msn milestone payment due
- $25.0 million in Q4 2026
- Share repurchase remaining
- $150.0 million (none repurchased in 2026)
- Cost of product sold pct q3
- 30.0% of net revenue (vs 24.9% prior year)
- Operating income nine months
- $180.8 million
- Net cash from operations nine months
- $196.9 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.